British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015



Similar documents
Mesothelioma Priority Setting Partnership. PROTOCOL November 2013

How To Prepare A Meeting For A Health Care Conference

Lung Cancer & Mesothelioma

The following information is only meant for people who have been diagnosed with advanced non-small cell

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

International Symposium on Malignant Pleural Mesothelioma

The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients

Statewide Respiratory Clinical Network

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Chapter 7: Lung Cancer

How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

Advances in Lung Cancer: A Multidisciplinary Approach

How To Treat Mesothelioma

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

Annual General Meeting of the. Faculty of Clinical Health Psychology. Agenda

The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes. UK Lung Cancer Coalition November 2012

How do I find the best place to get treatment for my lymphoma?

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

How To Contact The Lung Cancer And Mesothelioma Multi-Disciplinary Team

Scottish Medicines Consortium

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

TARGET YOUR FUTURE RADIATION ONCOLOGY

Lung Cancer in 2015: A Multidisciplinary Update

Salisbury Lung Cancer Service (1 of 5)

Full name/ Title of Medical Qualifications Eligible for Conditional Registration. American Board of Obstetrics and Gynaecology

Treatment of colon cancer

Division of Cancer Surgery Information Guide

How To Choose A Pediatric Oncologist

Targeted Therapies in Lung Cancer

targeted therapy a guide for the patient

SAKK Lung Cancer Group. Current activities and future projects

Lung SSG 6 th May 2015 Research

NCCN Non-Small Cell Lung Cancer V Update Meeting 07/09/10

Corporate Medical Policy

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

PATIENT INFORMATION SHEET

Ask Us About Clinical Trials

Memorandum. The Faculty of Public Health of the Royal Colleges of the United Kingdom. (Registered Charity No )

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group

Appendix 1 Current list of approved qualifications for Locum Tenens registration

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

POLICY A. INDICATIONS

A guide to prostate cancer clinical trials

A developmental framework for pharmacists progressing to advanced levels of practice

National Macmillan Mesothelioma Resource Centre. Bulletin April 2008 MESOTHELIOMA UK UPDATE

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK

SCR Expert Advisory Committee

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Manchester Pharmacy School.

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

National Lung Cancer Audit Report

IMA ANNUAL CONFERENCE 2014

Research Methods for Respiratory Diseases

The Bologna Process implications for UK and Irish medical schools

Summary of treatment benefits

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region

Treatment options for recurrent ovarian cancer

The Characteristics of an Effective Multidisciplinary Team (MDT)

2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)-

Lung Cancer: More than meets the eye

Professional Competence. Guidelines for Doctors

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

Keeping patients safe when they transfer between care providers getting the medicines right

UNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN

How To Treat Lung Cancer At Cleveland Clinic

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment

Targeted Therapy What the Surgeon Needs to Know

MARKETING & EXHIBITOR PROSPECTUS

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Curriculum Vitae. Name: Alison Richardson, Clinical Professor of Cancer Nursing & End of Life Care

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment

Improving healthcare for people with long-term conditions

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

A new predictive algorithm for aiding clinical decision-making in lung cancer

Transcription:

0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals involved with thoracic malignancies. BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and facilitating and nurturing clinical trial ideas into full protocols. The organisation now has a membership/e-circulation list of over 2,000 thoracic oncology health care professionals. BTOG members are from all professions involved in the care of lung cancer and mesothelioma throughout the UK and Ireland including medical and clinical oncologists, surgeons, radiotherapists, radiologists, nurses (specialist, research/trials, chemotherapy and academic), pharmacists and scientists. BTOG are a not for profit organisation which is kindly hosted by University Hospitals of Leicester NHS Trust (UHL) and the secretariat is based at Glenfield Hospital in Leicester. BTOG does not receive any funding from UHL or the NHS and at present receives financial support through sponsorship and educational grants from industry. BTOG Chair Professor Ken O Byrne formerly from St James s Hospital, Dublin and now Professor of Medical Oncology, Faculty of Health at Princess Alexander Hospital and Queensland University of Technology, Brisbane, Australia is the founding chair and president of BTOG. Dr Sanjay Popat (left), Consultant Medical Oncologist from the Royal Marsden Hospital, London took over the chair role in January 2013 (following BTOG 2013). Page 1 of 6

Education Programme of Events 13 th Annual BTOG Conference 2015 BTOG 2015 28 th to 30 th January 2015, Dublin BTOG 2015 attracted renowned speakers and chairs from the UK, Ireland, Europe, Australia, USA and Canada. The conference updated attendees on state of the art management of lung cancer and mesothelioma, increased understanding on the nature of clinical practice and research and facilitated networking for the development of new national and international clinical research studies in lung cancer and mesothelioma. Each year the British Thoracic Oncology Group (BTOG) gives a lifetime achievement award to an individual who in the steering committee s opinion has made a significant contribution to the management of thoracic malignancies in the UK and Ireland and this year this was presented to Dr Fergus Macbeth. BTOG 2015 was awarded 13 CPD Credits by the Royal Colleges of Physicians of the United Kingdom and 13 ESMO-MORA points category 1 by European Society for Medical Oncology (3 Wednesday and 6 Thursday and 4 Friday). The Royal College of Surgeons of England also awarded up to 10 points for Thursday and Friday. BTOG 2015 attracted 723 attendees. BTOG 2015 included 8 sponsored satellite meetings on Wednesday, Thursday and Friday and BTOG also held specialist symposia on Wednesday on the subjects of Translational Research, Respiratory Medicine and Radiotherapy Training. 800 700 600 500 400 300 200 100 0 BTOG Attendees 2003-2015 723 630 664 675 540 531 426 449 494 470 431 347 226 1 2 3 4 5 6 7 8 9 10 11 12 13 Year Feedback from BTOG 2015 Very good, well organised conference. Excellent discussion on topical areas surrounding thoracic medicine and surgery - particularly focus on ongoing research helpful and inspiring. Sessions ran to time and discussion encouraged. Wonderful conference. I thoroughly enjoyed all of the sessions, with a fantastic mix of topics ranging from basic science to surgery. The question and answer part of the talks were also very informative and useful. Superb mix of speakers and topics. The conference was excellent for networking and enhancing your clinical skills and knowledge. I attend BTOG most years and always learn a lot from an enjoyable meeting. I think the standard of talks was better than ever this year and the structure of the whole event had clearly been thought through carefully. Page 2 of 6

BTOG Thoracic Oncology Course 2014 12 th and 13 th May 2014 Leicester The course is aimed at trainees and those entering the thoracic oncology speciality and all members of the MDT. The course was awarded 9 CPD credits from the Royal College of Phycians. Attendance totalled 75. Feedback from BTOG Course 2014 Very informative 2 days, very well organised. Group sessions allow time for interaction/ questions. Really good/refreshing to go to a course which concentrates on practical, relevant day to day practice rather than aspirational future potential treatments. I am new to oncology and found the course very informative and useful. Very informative course, well organised, focussed on daily clinical practice. I really enjoyed the course, it was very relevant to my practice. The presenters were very receptive to questions. Managing Mesothelioma in the UK Meeting in collaboration with Mesothelioma UK 12 th September 2014 London The study day was awarded 5 CPD credits from the Royal College of Physicians. Attendance totalled 119. Feedback from Mesothelioma Meeting Excellent, interactive meeting. Well organised and structured, hotel location easy to find, quality of catering very high. Excellent, well done. Relevant and useful. Liked the trials roundup. Impressive speaker line-up. Good range of speakers. Thank you for the hard work put in to organising. The speakers were all fantastic and definitely gave us all something to think about. Very informative and an eye opener into research into mesothelioma. Very optimistic about the long term development in mesothelioma. Publications Supplement to Lung Cancer journal published by Elsevier BTOG 2015 posters Reference: Lung Cancer 87 Suppl. 1 (2015) ISSN 0169-5002 http://www.sciencedirect.com/science/journal/01695002 Page 3 of 6

A Practical Guide to Lung Cancer Nutritional Care published in January 2015. The BTOG steering committee was given the opportunity to comment on the draft guide and the final guide was endorsed by BTOG. http://lungcancernutrition.com/ BTS Guideline for the investigation and management of Pulmonary Nodules The BTOG steering committee was given the opportunity to comment on the draft guideline (to be published). Collaboration British Thoracic Society BTOG 2015 was held in collaboration with the British Thoracic Society, the European Thoracic Oncology Platform (ETOP), International Association for the Study of Lung Cancer (IASLC), Mesothelioma UK and National Lung Cancer Forum for Nurses (NLCFN). Collaborative sessions BTOG 2015 included the BTOG/British Thoracic Society (BTS)/ NCRI session, the BTOG/SCTS session and BTOG/NCRI subgroups workshops and BTOG/NLCFN workshop. Page 4 of 6

Representation BTOG has gained recognition as an appropriate body to review NICE submissions for new drug therapies for thoracic malignancies. Commentator: Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer [ID489] Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene [ID499] Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer [ID556] Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175) [ID620] Lung cancer (non-small cell, anaplastic lymphoma kinase positive, metastatic) - LDK378 (post chemotherapy) ID729 BTOG sent a written complaint to the Chair of the Cancer Drugs Fund (CDF) in February 2015 in relation to the decision to withdraw access to pemetrexed through the CDF. BTOG considered that withdrawal of maintenance pemetrexed from the CDF would be a backward step for NSCLC patients in England and would have a direct and negative impact on survival and outcomes. National Lung Cancer Audit Executive The BTOG steering committee is represented on this group by Dr Clive Mulatero (BTOG was invited to join the Executive January 2015). European Thoracic Oncology Platform (ETOP) www.etop.ch BTOG is a member group of ETOP and BTOG President Ken O Byrne and BTOG steering committee member Keith Kerr are both members of the ETOP foundation council. The interest in promoting and improving collaboration in clinical and translational research in lung cancer and mesothelioma in Europe prompted investigators representing collaborative study groups and institutions concerned with thoracic malignancies to explore new ways of working together. Out of this discussion the European Thoracic Oncology Platform was founded in 2009. International Mesothelioma Interest Group 2016 Local Organising Committee http://imig2016.org/imig-committees/local-organizing-committee/ BTOG is represented on this committee by Dr Sanjay Popat. Page 5 of 6

Steering Committee The steering committee met 4 times during this year April 2014, June 2014, October 2014 and January 2015. Please refer to Appendix A for list of steering committee members during this year. Website: www.btog.org BTOG Membership During this year membership was free of charge and there were >2,000 members. BTOG 2015 registrants (excluding industry) were given honorary membership of BTOG for 1 year from 1 January 2015 to 31 December 2015. The benefits of BTOG membership include:- access to the BTOG website (www.btog.org) member area including the document library (including presentations from the annual conference and study days subject to speaker permissions) notification of BTOG annual conference and study days chance to attend BTOG study days that, subject to sponsorship, are offered free of charge for health care professionals involved in thoracic oncology and travel bursaries are also available for travel within the UK and Ireland notification of thoracic oncology conferences/study days/other events circulation of thoracic oncology research and other news related to lung cancer and mesothelioma participation in research (questionnaires, surveys) The British Thoracic Oncology Group Charity (BTOG Charity) During this year Dawn Mckinley, BTOG Operational Manager and steering committee members, John Edwards and Mick Peake have continued to work relating to the setting up of the BTOG Charity. This will be completed during 2015. Page 6 of 6